PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2009
CASE
AUTH/2204/1/09 AstraZeneca

AstraZeneca breached Clause 9.5 by referencing the MHRA in a Zoladex journal advertisement (AUTH/2204/1/09)

MHRA complained that a Zoladex (goserelin) journal ad referenced the MHRA. The Panel ruled this breached Clause 9.5 (no exemption applied). AstraZeneca…

2008
CASE
AUTH/2164/9/08 Takeda

AUTH/2164/9/08: MSD v Takeda – Actos/Competact ad implied CV event reduction and misused β€œindependent”

A pioglitazone journal ad implied CV event reduction as part of the product’s benefits and called a Takeda-funded meta-analysis β€œindependent”. Breaches of…

2008
CASE
AUTH/2173/10/08 Syner-Med

AUTH/2173/10/08: Nurse v Syner-Med – Ferinject detail aid and misleading administration information

A nurse challenged a Ferinject detail aid as inaccurate. The PMCPA found the CosmoFer administration chart and a β€œSingle dose delivery” claim…

2009
CASE
AUTH/2270/10/09 Merz Pharma UK ⭐ Case of the Week

AUTH/2270/10/09: Allergan v Merz Pharma β€” β€œAt least as effective as Botox” claim based on non-inferiority studies

Merz’s exhibition claim that Xeomin was β€œat least as effective as Botox” was ruled misleading because the cited studies were non-inferiority trials…

2009
CASE
AUTH/2252/7/09 CV Therapeutics

AUTH/2252/7/09: Professor v CV Therapeutics Europe (Ranexa) – memory stick seen as inducement to secure an interview

A professor said a rep refused to leave a Ranexa memory stick unless she saw him, creating an impression of inducement. Breach…

2009
CASE
AUTH/2232/5/09 Cephalon

Cephalon: Uncertified Effentora launch training materials and inadequate representative training (AUTH/2232/5/09)

Former rep alleged poor Code training and uncertified Effentora launch materials. PMCPA found breaches for uncertified briefing materials and inadequate/undocumented training, but…

2009
CASE
AUTH/2285/12/09 Beacon Pharmaceuticals

AUTH/2285/12/09: Consultant Neurologist v Beacon (Episenta letters) – No breach (Clause 7.2)

Beacon’s mailing claimed Episenta was bioequivalent to and interchangeable with Epilim Chrono. A neurologist said this conflicted with epilepsy guidance on avoiding…

2009
CASE
AUTH/2290/12/09 Astellas Pharma

Astellas Mycamine advisory boards ruled disguised promotion and inducement (AUTH/2290/12/09)

Anonymous clinician alleged Mycamine advisory boards were promotional and attendees were profiled for follow-up. PMCPA found disguised promotion, inducement via fees, and…

2010
CASE
AUTH/2316/5/10 Flynn Pharma ⭐ Case of the Week

Flynn Pharma: competitor disparagement in rep training and discussion about Abstral during Actiq promotion (AUTH/2316/5/10)

A palliative medicine consultant complained about an Actiq rep’s comments on competitor Abstral. The Panel found misleading/disparaging competitor messaging and inadequate training…

2010
CASE
AUTH/2294/1/10 AstraZeneca

AstraZeneca: Seroquel ad claim of β€œfavourable weight profile” ruled misleading (AUTH/2294/1/10, AUTH/2296/1/10, AUTH/2297/1/10)

PMCPA ruled a UK journal ad for Seroquel misleading for implying an advantage on weight gain (β€œfavourable weight profile across the full…

2010
CASE
AUTH/2331/7/10 Eli Lilly

Novo Nordisk v Lilly: Byetta promotional meeting linked to pre-diabetes discussion (AUTH/2331/7/10)

A Byetta-branded promotional meeting included a pre-diabetes presentation. PMCPA ruled this created an inevitable association with Byetta and implied off-licence use, breaching…

2009
CASE
AUTH/2234/5/09 Novo Nordisk

AUTH/2234/5/09: Novo Nordisk ruled in breach for repeated pre-licence promotion of Victoza (liraglutide) via website, journal insert and meetings

Novo Nordisk was found in breach for promoting unlicensed liraglutide (Victoza) before UK authorisation via an β€œeducational” website, a paid journal insert…

2015
CASE
Otsuka

Employee complaint: Otsuka Europe/Otsuka UK delays updating SPCs, eMC and prescribing information (Jinarc, Samsca, Abilify)

Employee alleged weak processes meant SPC/prescribing info updates weren’t communicated/implemented promptly. Panel found multiple breaches (Clauses 2, 4.1, 9.1) and governance failures;…

2019
CASE
AUTH/3171/3/19 Novartis Pharmaceuticals UK ⭐ Case of the Week

AUTH/3171/3/19: Health professional v Novartis β€” meeting attendance certificate (no breach)

A health professional alleged a rep used delivery of an attendance certificate to secure a follow-up meeting (Clause 15.3). The Panel found…

2018
CASE
AUTH/3112/11/18 Eli Lilly

Lilly rheumatology website: β€œshare by email” templates breached high standards (AUTH/3112/11/18)

Complaint about Lilly’s rheumatology HCP website. Most allegations not upheld, but β€œshare by email” templates didn’t make Lilly’s involvement clear to recipients,…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training